MARKET

VIR

VIR

VIR BIOTECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.39
-0.66
-1.78%
Closed 18:16 07/29 EDT
OPEN
37.99
PREV CLOSE
37.05
HIGH
37.99
LOW
36.08
VOLUME
479.16K
TURNOVER
--
52 WEEK HIGH
141.01
52 WEEK LOW
25.31
MARKET CAP
4.73B
P/E (TTM)
-11.7562
1D
5D
1M
3M
1Y
5Y
Earnings Preview: Vir Biotechnology, Inc. (VIR) Q2 Earnings Expected to Decline
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 15h ago
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track
Zacks.com · 19h ago
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 ...
Insider Monkey · 1d ago
Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment
Shares of Vir Biotechnology Inc. gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline said the European Commission purchased 220,00 doses of their investigational COVID-19 antibody treatment. The therapy is a single-dose mono...
MarketWatch · 1d ago
European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody
Benzinga · 1d ago
GSK, Vir Bio ink joint procurement agreement with EC for COVID-19 treatment, sotrovimab
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) have signed a Joint Procurement Agreement with the European Commission ((EC)) to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2
Seekingalpha · 1d ago
GlaxoSmithKline, Vir Biotechnology to Supply Covid-19 Treatment to European Commission
marketwatch.com · 1d ago
UPDATE 1-EU signs deal with GSK for supply of potential COVID drug
reuters.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIR. Analyze the recent business situations of VIR BIOTECHNOLOG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIR stock price target is 81.17 with a high estimate of 135.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 187
Institutional Holdings: 75.77M
% Owned: 58.27%
Shares Outstanding: 130.04M
TypeInstitutionsShares
Increased
37
2.71M
New
39
1.14M
Decreased
63
4.29M
Sold Out
25
2.78M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Vicki Sato
President/Chief Executive Officer/Director
George Scangos
Chief Financial Officer/Secretary
Howard Horn
Executive Vice President/Chief Scientific Officer
Herbert Virgin
Chief Technology Officer
Ann Hanly
Chief Administrative Officer
Steven Rice
Other
Phil Pang
Independent Director
Jeffrey Hatfield
Independent Director
Robert More
Independent Director
Janet Napolitano
Independent Director
Robert Nelsen
Independent Director
Dipchand Nishar
Independent Director
Robert Perez
Independent Director
Saira Ramasastry
Independent Director
Phillip Sharp
Independent Director
Elliott Sigal
No Data
About VIR
Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Webull offers kinds of Vir Biotechnology Inc stock information, including NASDAQ:VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.